ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor (Ki
values are 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A respectively). Induces G2
/M phase cell cycle arrest and apoptosis. Downregulates the expression of antiapoptotic proteins such as Bcl-2 and survivin and enhances downstream p53 signaling in acute myeloid leukemia (AML).
Soluble to 50 mM in DMSO
Store at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The CDK1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.
Kojima et al.
Cancer Sci., 2009;100:1128
CDK1 regulates mediator of DNA damage checkpoint 1 during mitotic DNA damage.
Yu et al.
Cancer Res., 2012;72:5448
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1.
Vassilev et al.
The citations listed below are publications that use Tocris products. Selected citations for Ro 3306 include:
Showing Results 1 - 4 of 4